TMCnet News

Research and Markets: Cardiovascular Disease Market in Asia-Pacific Expected to Grow Gradually
[January 06, 2014]

Research and Markets: Cardiovascular Disease Market in Asia-Pacific Expected to Grow Gradually


DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/pgp8g5/cardiovascular) has announced the addition of the "Cardiovascular Diseases Therapeutics Market in Asia Pacific to 2019 - Promising Pipeline Drugs to Offset Revenue Decline from Generic Erosion and Off-Label Use" report to their offering.

The market for Cardiovascular Disease (CVD) - comprising heart failure, myocardial infarction and Acute Coronary Syndrome (ACS (News - Alert)) - has registered modest growth from 2007-2012 the period due to the launch of various blockbuster drugs. The market is expected to grow at a gradual rate over the forecast period from 2012 to 2019, due to the patent expiry of a number of blockbuster drugs, including Lipitor (atorvastatin) and Plavix (clopidogrel).

The value of the CVD market in India, Australia China and Japan amounted to an estimated $7.61 billion in 2012, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 1.4% over the forecast period to reach $8.39 billion in 2019. The Chinese market accounted for a reported 69% share of the Asia-Pacific (APAC) market in 2012, followed by India with 17%. The market is expected to grow moderately due to an increase in the elderly population and overall population growth in countries such as China and India.



Asia-Pacific Region Second to North America in Terms of Licensing Agreements for Pharmaceutical Players

The APAC region was the most opportunistic region after North America during the period from 2007 to 2013 in terms of licensing deals in the pharmaceutical industry. A large amount of these deals - around 32% - took place exclusively in this region during this period. The fiscal year ended 2009 accounted for the highest share of licensing deals in terms of volume, with a total of $3.5 billion, equivalent to around 19% of the total licensing deals for all three cardiovascular indications.


Key Topics Covered:

List of Tables

List of Figures

Introduction

Therapeutic Landscape

Marketed Products

Pipeline Analysis

Market Forecast to 2019

Deals and Strategic Consolidations

Appendix

List of Tables

List of Figures

For more information visit http://www.researchandmarkets.com/research/pgp8g5/cardiovascular

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


[ Back To TMCnet.com's Homepage ]